However, no studies have investigated whether CK1α inactivation, especially in the MM BM microenvironment, could affect the cytotoxic effects of novel drugs, such as Lena, in the therapy of this hematological malignancy. This evidence concerns the gene CSNK1A1 and hematologic disorder.